Recurrent and Metastatic Head and Neck Cancers
Publication Date: December 15, 2022
Key Points
Key Points
- Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
- Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
- The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.
Treatment
Treatm...
...ecommendation 1.1Programmed death-lig...
...mendation 1.2PD-L1 combined positive score...
...on 1.3Tumor mutational burden (TMB) testin...
...mendation 1.4TMB ≥10 should be int...
...ndation 2.1Pembrolizumab monotherapy or pembrolizu...
...2.2Pembrolizumab, platinum, and 5-FU...
...ommendation 3.1Pembrolizumab or nivolumab sh...
Recommendation 4.1Toripalimab, camre...
...n 4.2Programmed cell death protein 1 (PD-...
...commendation 5.1For patients with oligo...
...ation 6.1Pembrolizumab may be offered...
...tion 6.2Pembrolizumab may be offered to patie...
...kers and Recommendations by PD-L1 Stat...
...2. Recommendations by Subtype...